GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » 3-Year FCF Growth Rate

Vicore Pharma Holding AB (OSTO:VICO BTA) 3-Year FCF Growth Rate : 31.20% (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB 3-Year FCF Growth Rate?

Vicore Pharma Holding AB's Free Cash Flow per Share for the three months ended in Mar. 2025 was kr-7.57.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 5.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Vicore Pharma Holding AB was 31.20% per year. The lowest was -35.50% per year. And the median was -19.40% per year.


Competitive Comparison of Vicore Pharma Holding AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Vicore Pharma Holding AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 3-Year FCF Growth Rate falls into.


;
;

Vicore Pharma Holding AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Vicore Pharma Holding AB  (OSTO:VICO BTA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Vicore Pharma Holding AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines